The initial hormone receptor/HER2 subtype is the main determinator of subtype discordance in advanced breast cancer: a study of the SONABRE registry.
Meegdes M, Ibragimova KIE, Lobbezoo DJA, Vriens IJH, Kooreman LFS, Erdkamp FLG, Dercksen MW, Vriens BEPJ, Aaldering KNA, Pepels MJAE, van de Winkel LMH, Tol J, Heijns JB, van de Wouw AJ, Peters NAJB, Hochstenbach-Waelen A, Smidt ML, Geurts SME, Tjan-Heijnen VCG.
Meegdes M, et al. Among authors: kooreman lfs.
Breast Cancer Res Treat. 2022 Apr;192(2):331-342. doi: 10.1007/s10549-021-06472-5. Epub 2022 Jan 13.
Breast Cancer Res Treat. 2022.
PMID: 35025003
Free PMC article.